FIGURE
Figure 2.
- ID
- ZDB-FIG-250214-24
- Publication
- Wawruszak et al., 2025 - Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies
- Other Figures
- All Figure Page
- Back to All Figure Page
Figure 2.
Evaluation of single drug-mediated effects on the viability of the (a) MCF7 and (b) T47D luminal A BC, (c) BJ normal, and (d) MDA-MB-231, (e) BT-549 and (f) MDA-MB-468 BC cells in the MTT assay. BC cells were exposed for 96 h to increasing EX527 concentrations (10–200 µM). The data are presented as the mean ± standard deviation (±SD) of the mean. * |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ J Enzyme Inhib Med Chem